SCHEMBL11909253

SCHEMBL11909253

CCCCOc1ccc(F)c(-c2ccc(N)c(C(=O)O)n2)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.37
CYP1A2 P05177 2/20 0.35
XDH P47989 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PLA2G2D Q9UNK4 1/20 0.35
HTR2C P28335 2/20 0.35
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
MCL1 Q07820 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
SLC6A2 P23975 1/20 0.34
SCN1A P35498 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
HIF1A Q16665 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN3A Q9NY46 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907614 0.94 PIM2 (0.35) PPARDCYP1A2XDHCYP2C19CYP2D6
SCHEMBL11907553 0.90 FGFR2 (0.41) TSHR
SCHEMBL11909552 0.83 LMNA (0.38) HIF1A
SCHEMBL11908264 0.83 PPARD (0.38) PPARDPLA2G2DHTR2CTHRATHRB
SCHEMBL11907548 0.81 FFAR4 (0.41) XDHMCL1
SCHEMBL11907367 0.81 DHFR (0.42) TSHR
SCHEMBL11907325 0.78 MRGPRX4 (0.41) MCL1
SCHEMBL11908883 0.78 MAPT (0.36) PPARDCYP1A2CYP2C19CYP2D6SCN1A
SCHEMBL11907340 0.78 CYP1A2 (0.35) CYP1A2CYP2C19PLA2G2DTHRATHRB
SCHEMBL1711905 0.74 PIM1 (0.53) PPARDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 PPARD 1955/4885CYP1A2 4415/4885XDH 2634/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 PPARD 1955/4885CYP1A2 4415/4885XDH 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.